Logo

AVBP

ArriVent BioPharma, Inc. Common Stock

AVBP

ArriVent BioPharma, Inc. Common Stock • NASDAQ
$22.94 ▼ -0.48% (-0.11)
Market Cap $946.95 M
52w High $30.41
52w Low $15.47
Dividend Yield 0%
P/E -5.53
Volume 126.56K
Outstanding Shares 41.28M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $38.316M ▲ $-34.978M ▼ 0% $-0.83 ▲ $-34.978M ▼
Q2-2025 $0 $33.623M ▼ $-31.399M ▲ 0% $-0.9 ▲ $-31.399M ▲
Q1-2025 $0 $66.772M ▲ $-64.387M ▼ 0% $-1.9 ▼ $-66.772M ▼
Q4-2024 $0 $23.705M ▼ $-20.633M ▼ 0% $-0.61 $-23.705M ▲
Q3-2024 $0 $24.232M $-20.564M 0% $-0.61 $-24.232M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $300.266M ▲ $326.555M ▲ $21.558M ▲ $304.997M ▲
Q2-2025 $235.687M ▲ $269.506M ▲ $19.636M ▲ $249.87M ▲
Q1-2025 $176.077M ▼ $215.495M ▼ $12.953M ▼ $202.542M ▼
Q4-2024 $218.863M ▼ $274.942M ▼ $17.288M ▲ $257.654M ▼
Q3-2024 $282.855M $292.711M $15.218M $277.493M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.978M ▼ $-35.798M ▼ $-50.76M ▼ $86.465M ▲ $-93K ▼ $-35.798M ▼
Q2-2025 $-31.399M ▲ $-26.124M ▲ $13.91M ▼ $75.114M ▲ $62.9M ▲ $-26.124M ▲
Q1-2025 $-64.387M ▼ $-68.008M ▼ $36.821M ▲ $6.759M ▲ $-24.428M ▲ $-68.008M ▼
Q4-2024 $-20.633M ▼ $-16.152M ▲ $-192.465M ▼ $55K ▼ $-208.562M ▼ $-16.152M ▲
Q3-2024 $-20.564M $-16.345M $0 $531K $-15.814M $-16.345M

Five-Year Company Overview

Income Statement

Income Statement ArriVent is still a pure R&D story with no product revenue yet. All activity runs through research and operating expenses, so the company has been reporting steady losses each year. Those losses have gradually increased as development programs have advanced and the organization has grown, which is typical for a clinical‑stage biotech building toward late‑stage trials. Profitability is not in sight until at least one drug is approved and commercialized, so investors should view the income statement as a reflection of investment in the pipeline rather than current business performance.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. Assets are dominated by cash and equivalents, with no financial debt reported. Equity has grown over time as the company raised capital, which has helped support expanded R&D. The lack of leverage lowers financial risk, but the overall asset base is limited, underscoring that ArriVent remains an early‑stage company that will likely need additional funding over time as trials progress and costs rise.

Cash Flow

Cash Flow Cash flows are negative because the business is funding research and operations without bringing in product sales. Operating cash burn has increased gradually as the pipeline has advanced, and there is effectively no meaningful spending on physical assets, so free cash flow tracks closely with operating outflows. Sustainability of the cash profile will depend on access to new capital, partnership payments, or milestone revenues, which is a common pattern across development‑stage biotechs.

Competitive Edge

Competitive Edge ArriVent’s competitive position rests on a focused niche strategy rather than scale. The lead drug, firmonertinib, targets genetically defined lung cancer patients who are not well served by current treatments, including some mutation types with little or no direct competition. Regulatory recognition and encouraging early clinical data provide an initial edge, but the company still faces significant competition from larger oncology players developing next‑generation targeted therapies. Its in‑licensing model and global sourcing of assets allow it to move quickly and efficiently, though it also makes ArriVent dependent on the strength and exclusivity of its partnerships.

Innovation and R&D

Innovation and R&D Innovation is the core of ArriVent’s story. The company is built around precision oncology, with firmonertinib as a potentially differentiated EGFR inhibitor designed to address difficult lung cancer mutations and brain metastases. Beyond this, ArriVent is assembling a portfolio of antibody‑drug conjugates using advanced technologies from multiple partners, aiming for more targeted and potent cancer therapies. This partnership‑heavy approach lets ArriVent tap into cutting‑edge platforms without building everything in‑house, but it also means successful execution will depend on clinical results and smooth collaboration with external innovators.

Summary

ArriVent is an early‑stage oncology biotech with no commercial products yet, funded primarily by equity and focused on advancing a promising but still unproven pipeline. The financials show a typical pre‑revenue profile: recurring losses, negative cash flow, and a balance sheet centered on cash with no debt. The real value driver is the scientific and clinical potential of firmonertinib and the emerging ADC portfolio, supported by a network of global partnerships. Going forward, the key factors to watch are clinical trial outcomes, regulatory milestones, and the company’s ability to secure sufficient funding to carry its programs through late‑stage development and, eventually, commercialization.

NEWS

November 10, 2025 · 8:00 AM UTC

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Read more

September 22, 2025 · 4:05 PM UTC

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Read more

September 9, 2025 · 8:00 AM UTC

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Read more